December 23, 2025

Shares of Novo Nordisk A/S jumped sharply in U.S. premarket trading on Tuesday after regulators approved an oral version of its blockbuster weight-loss drug Wegovy, giving investors a rare positive headline in a year marked by earnings downgrades and clinical setbacks.

U.S.-listed shares rose as much as 7–8% before the open, paring part of a steep 2025 decline that had pushed the stock to multi-year lows. The move followed clearance from the U.S. Food and Drug Administration for an oral formulation of Wegovy, making it the first pill-based GLP-1 therapy approved in the U.S. specifically for chronic weight management.

A strategic win in obesity care

The approval gives Novo Nordisk a new delivery option for semaglutide, the active ingredient behind Wegovy and diabetes drug Ozempic. By removing the need for injections, the pill could expand the addressable market to patients reluctant to use weekly shots and potentially improve adherence — a key issue for long-term weight-loss therapies.

The decision also sharpens Novo’s competitive positioning against rivals, most notably Eli Lilly, whose injectable GLP-1 drugs have been gaining share and whose oral candidates remain in development.

Context: a difficult 2025

The regulatory win arrives after a turbulent year. Novo Nordisk shares are down more than 40% year-to-date, pressured by slower U.S. growth for Wegovy and Ozempic, supply constraints, pricing pressure tied to rebates and U.S. drug-pricing reforms, and intensifying competition. Sentiment deteriorated further late in the year after a closely watched Alzheimer’s trial using semaglutide failed to meet its primary endpoint, extinguishing hopes of a near-term expansion into neurology.

Management has responded by refocusing the pipeline on core metabolic indications while continuing to invest heavily in manufacturing capacity. Despite the stock’s volatility, the company has continued to generate strong cash flows and to return capital via dividends and buybacks.

What analysts are saying

The sharp premarket move highlights how expectations around Novo Nordisk remain divided after a volatile year. While the FDA approval of oral Wegovy is widely viewed as strategically positive, analysts continue to differ on how quickly the product can translate into renewed earnings momentum amid competitive and pricing pressures.

Based on publicly available consensus data, 12-month price targets for Novo Nordisk’s U.S.-listed shares generally cluster in the low-to-mid $50s, with the highest estimates extending toward the upper-$60s and the most cautious views in the low-$40s. The dispersion reflects contrasting assumptions around patient uptake, reimbursement dynamics, manufacturing scale-up and the durability of GLP-1 pricing in the U.S. market.

More constructive analysts point to Novo Nordisk’s scale in obesity care, expanding production capacity and the potential for improved adherence with an oral option as factors that could support longer-term growth. More cautious voices continue to flag competitive intensity, margin pressure and execution risk following a year marked by earnings warnings and clinical disappointments.

Overall, Street consensus implies upside from recent trading levels, though expectations remain well below the peak valuations seen earlier in the GLP-1 rally, underscoring a more measured outlook heading into 202

Trend line

The approval of oral Wegovy provides a near-term catalyst that could stabilize sentiment after months of negative revisions. Analysts say the key questions now shift to launch timing, payer coverage, adherence data and manufacturing scale-up, as well as whether the pill can meaningfully offset slower growth in injectables. Competitive responses from Eli Lilly and reimbursement decisions in the U.S. will remain central to the stock’s trajectory into 2026.

Disclosure / compliance note

This article is a journalistic summary of publicly available information and third-party analyst views. It does not constitute investment advice, a recommendation, or a solicitation to buy or sell securities. Price targets cited are those of the respective brokers and are subject to change. Readers should consult original company filings and analyst reports for full context.